Malignant pleural mesothelioma (MPM) is a relatively rare but aggressive form of cancer arising from the membrane covering the lungs and the inner side of the ribs. This type of cancer is most frequently a result of inhaling asbestos.
This report contains market size and forecasts of Malignant Pleural Mesothelioma Treatment in global, including the following market information:
Global Malignant Pleural Mesothelioma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Malignant Pleural Mesothelioma Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Malignant Pleural Mesothelioma Treatment companies in 2021 (%)
The global Malignant Pleural Mesothelioma Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Pemetrexed Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Malignant Pleural Mesothelioma Treatment include Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical and Mylan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Malignant Pleural Mesothelioma Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Malignant Pleural Mesothelioma Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Pleural Mesothelioma Treatment Market Segment Percentages, by Type, 2021 (%)
Pemetrexed
Cisplatin
Others
Global Malignant Pleural Mesothelioma Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Pleural Mesothelioma Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Malignant Pleural Mesothelioma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Malignant Pleural Mesothelioma Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Malignant Pleural Mesothelioma Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Malignant Pleural Mesothelioma Treatment revenues share in global market, 2021 (%)
Key companies Malignant Pleural Mesothelioma Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Malignant Pleural Mesothelioma Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals